CIK 0001711279
- Large accelerated filer
Krystal Biotech, Inc.
Sign in to watch- Ticker
- KRYS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 821080209
- Phone
- +1 412-586-5830
- Business address
- 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $17,966,069
- in 2 filings, $18.0M under 10b5-1 plans
Net −$17,966,069. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −2,099 | $172.24 | $362K | 1,547,883 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −1,206 | $173.41 | $209K | 1,546,677 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −1,724 | $174.50 | $301K | 1,544,953 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −4,975 | $175.33 | $872K | 1,539,978 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −5,867 | $176.38 | $1.0M | 1,534,111 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −6,358 | $177.38 | $1.1M | 1,527,753 |
| 2024-06-11 | Krishnan Krish S President and CEO | Sale 10b5-1 | −1,871 | $178.14 | $333K | 1,525,882 |
| 2024-05-20 | Gangolli Julian S Director | Option exercise | +20,000 | $22.75 | $455K | 20,000 |
| 2024-05-20 | Gangolli Julian S Director | Sale | −10,930 | $163.71 | $1.8M | 9,070 |
| 2024-05-20 | Gangolli Julian S Director | Sale | −7,090 | $164.34 | $1.2M | 1,980 |
| 2024-05-20 | Gangolli Julian S Director | Sale | −1,980 | $165.76 | $328K | 0 |
| 2024-05-20 | Gangolli Julian S Director | Option exercise · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −2,658 | $168.15 | $447K | 1,573,224 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −1,646 | $168.96 | $278K | 1,571,578 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −8,040 | $170.42 | $1.4M | 1,563,538 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −5,469 | $171.09 | $936K | 1,558,069 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −2,800 | $172.21 | $482K | 1,555,269 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −3,587 | $173.30 | $622K | 1,551,682 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −800 | $174.13 | $139K | 1,550,882 |
| 2024-03-11 | Krishnan Suma President, R&D | Sale 10b5-1 | −2,146 | $167.99 | $361K | 1,635,116 |
Page 21 of 42 · 828 trades